Oncology Clinical Trials

Drug Development Resources and Case Studies

Oncology Clinical Trials

$995.00

This data-driven report focuses exclusively on Phase 1, 2 and 3 benchmarks for 29 oncology clinical trials across more than 10 primary oncology indications. Purchase this report to benchmark oncology clinical trials with individual and average per-patient and per-patient-per-month costs for each development phase. Compare average planned and actual trial duration while seeing how timelines influence total costs — and see how outsourcing can help. Control budgets, set staffing levels and track key cost-drivers of oncology clinical trials.

  • Description
  • Additional information

REPORT HIGHLIGHTS

 

Oncology Clinical Trials: Drug Development Resources and Case Studies

  • Publication Date: February 2013
  • Pages: 209
  • Chapters: 3
  • Metrics: 500+
  • Charts/Graphics: 140+

Data collected from 29 oncology clinical trials in:

  • Breast Cancer
  • Liver Cancer (HCC)
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • Prostate Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Solid Tumors
  • Leukemia
  • Colorectal Cancer
  • …and more

Detailed trial profiles for each phase:

  • Regional data (country level)
  • Staffing data
  • Trial cost
  • Timeframes
  • Trial sizes
  • Other cost metrics
Report Features

This data-driven report focuses exclusively on Phase 1, 2 and 3 benchmarks for 29 oncology trials across more than 10 primary oncology indications. It includes detailed trial case studies that create comprehensive snapshots to improve oncology trial operations. Track the shifting impact of key cost-drivers, such as patient enrollment and trial duration, as a product moves through development. At the same time, see how an adequate number of sites encourages patient enrollment — a critical challenge
for any trial.

Reason to Buy

Benchmark oncology trials of different sizes and durations with individual and average per patient and per patient per month costs for each development phase. Compare average planned and actual trial duration while seeing how trial duration influences total costs — and see how outsourcing can help. Track the shifting impact of key cost-drivers, such as patient enrollment and trial duration, as a product moves through development. At the same time, see how an adequate number of sites encourages patient enrollment — a critical challenge for any trial.

Target Audience

Pharmaceutical and biotechnology executives, directors, and managers involved in the following areas should consider purchasing this report:
– Oncology therapeutic area leaders
– Oncology franchise heads
– Clinical development and operations
– Clinical trial management
– Oncology research

Chapter Example

The US National Cancer Institute estimated that 2012 saw 1.6 million newly diagnosed cancer cases and a total of 577,000 cancer deaths in the United States alone. According to the World Health Organization, 7.6 million people died from cancer in 2008. Incidence rates of prostate cancer in US men have risen to 1.4 for every 1,000. Furthermore, a commonly held theory asserts that one out of every nine women will develop breast cancer at some point in their lives. In one way or another, cancer affects everyone.

The pharmaceutical industry has taken clear steps to address the medical community’s unmet oncology needs. According to the data service BioPharm Insight, oncology research is the most active therapeutic area. Oncology boasts 10,303 active drug programs, accounting for 18% of all drug programs. illustrates the current status of the top 10 areas of cancer research. More common diseases such as breast cancer and prostate cancer have been studied extensively. In fact, great breakthroughs have been made, including 188 approved treatments for breast cancer and 99 for prostate cancer.